Protocol Ledger

NCT07209462 · Phase II · RECRUITING

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

Interventional Phase II clinical trial protocol NCT07209462 sponsored by Mirum Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-22 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07209462
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07209462
Protocol FieldVerified Registry Value
NCT IdentifierNCT07209462
Consolidated Lead SponsorMirum Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2025-11-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI